Interview with Mal Eutick, CEO, Phebra Australia
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Address: 332 Burns Bay Road, Lane Cove, NSW 2066, Australia
Tel: +61 (0) 2 9420 9199
Web: http://www.phebra.com.au/
Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital market.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of pharmaceuticals in important disease areas such as anti-infectives, antidotes, diagnostic dyes and agents, oncology, pain and other specialty pharmaceuticals.
Our products are distributed in Australia, New Zealand, Asia, Canada and Europe.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of products in the following therapeutic areas:
anti-infectives
antidotes
cardiovascular and respiratory disease
central nervous system
diagnostic dyes and agents
infusion solutions, intravenous additives and electrolyte replacement solutions
oncology and pain
vitamins
specialty pharmaceuticals
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
Australia, the “land down under” to many Westerners, is sometimes left at just that — out of sight, and out of mind. But investors who ignore Australia do so…
See our Cookie Privacy Policy Here
